Howard Kartstein is Director of Business Development at GeneCentric, helping pharma to translate the complexity of tumor biology and create predictive response signatures. Prior to joining GeneCentric, Howard was a charter member of the Owlstone Medical business team developing the emerging science of Breath Biopsy. He helped clinicians to identify Inherited Metabolic Disorders and resolve diagnostic odysseys at Metabolon Precision Medicine and before (re)joining Metabolon, he managed a five-person sales team for Eurofins Pharma Discovery and directed client interactions for companies using Second Genome’s microbiome profiling and analysis services. Howard developed Metabolon’s pharmaceutical and consumer health franchises and has worked in sales and marketing for product and service companies including Cerep, Genzyme, PerSeptive Diagnostics and Seragen. He received his degree in microbiology from the University of New Hampshire, his advisors including Richard Blakemore, William Chesbro, Denise Maratea, Tom Pistole and Robert Zsigray.